Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.
about
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasSystemic Front Line Therapy of Follicular Lymphoma: When, to Whom and HowThe clinical development of obinutuzumab for the treatment of follicular lymphoma.Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.FDG-PET Scan: a new Paradigm for Follicular Lymphoma ManagementDynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.FDG PET/CT imaging as a biomarker in lymphoma.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.VI. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis.FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy.Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.Transformed follicular lymphoma.18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014.Unmet needs in the first-line treatment of follicular lymphoma.Overestimated value of FDG-PET based bone marrow evaluation in lymphoma: Response to Adams and Kwee.FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
P2860
Q26752284-CC6B040F-D8E5-420E-BDBC-F037C0FBB9B0Q28073262-2FDF0B1D-BD5C-4259-A72A-1F09BA428212Q33565265-64F9500E-37E4-41CE-8594-F97047C3882CQ33574197-F0DD23FD-EB16-4BAA-A126-89821607E1D1Q33642244-77F55BA6-E96E-44E1-BA20-4A8B21407C09Q37035820-BDE11FFD-1F05-4781-9334-6AB237EDE77CQ37672472-62F549DF-43E7-4A6B-9677-CD3986B38D4CQ38312367-8E29A215-0BB8-4B2F-AEA3-02458F0305DAQ38394272-A7118DBA-890E-4E26-9D9F-DD8BAB9BDF71Q38523981-6EB2D64B-9CC2-4BB2-92CF-6B84359E83F8Q38836081-CCB536D7-47F0-4A0E-9932-797311A4B364Q40533698-ED50DB8E-515D-4397-B225-1BF3543C3725Q41008736-CF89A66D-1582-41E4-8223-D672AA096D32Q42427611-4F7A7E16-D6FE-482B-BB12-DA12021399C6Q46450889-03DAC5AC-0F1D-4F21-8F87-59BAED4B4673Q47771789-B2DF1976-28FD-405D-A86B-9AD14B60101BQ47808320-3C4E9671-A3AF-434A-B08A-F96BC489B546Q49027912-0B5EA78D-D2F0-4AD6-80F5-95795D3C92B0Q50710717-3750FCF8-CFB0-4BCF-9CC9-AC12FB9AF2F6Q52981841-10FEF86B-61CD-499B-88F0-FC597924D4B3Q52982144-286AEE07-E75A-48B3-9D39-0C722757BF0F
P2860
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Prognostic value of PET-CT aft ...... in three multicentre studies.
@en
type
label
Prognostic value of PET-CT aft ...... in three multicentre studies.
@en
prefLabel
Prognostic value of PET-CT aft ...... in three multicentre studies.
@en
P2093
P50
P1476
Prognostic value of PET-CT aft ...... in three multicentre studies.
@en
P2093
Alina Berriolo-Riedinger
Anne Julian
Annibale Versari
Antonella Franceschetto
Christelle Tychyj
Fabien Ricard
Gilles Salles
Hervé Tilly
Jehan Dupuis
Luigi Marcheselli
P304
P356
10.1016/S2352-3026(14)70008-0
P577
2014-09-17T00:00:00Z